22157.jpg
2021 Global Chronic Venous Ulceration (CVU) Market Report, Featuring Rheacel, MediWound and Tissue Tech
April 26, 2021 04:03 ET | Research and Markets
Dublin, April 26, 2021 (GLOBE NEWSWIRE) -- The "Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's...
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
July 15, 2019 09:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
January 09, 2019 09:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...